6.4(top 5%)
impact factor
2.7K(top 10%)
papers
52.6K(top 5%)
citations
85(top 10%)
h-index
6.6(top 5%)
impact factor
3.7K
all documents
54.9K
doc citations
118(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1Carbonic anhydrase inhibitors and their therapeutic potentialExpert Opinion on Therapeutic Patents2000485
2Antiglaucoma carbonic anhydrase inhibitors: a patent reviewExpert Opinion on Therapeutic Patents2013273
3Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005 – 2013)Expert Opinion on Therapeutic Patents2013252
4Antiobesity carbonic anhydrase inhibitors: a literature and patent reviewExpert Opinion on Therapeutic Patents2013246
5Applications of carbonic anhydrase inhibitors and activators in therapyExpert Opinion on Therapeutic Patents2002243
6Silver and its application as an antimicrobial agentExpert Opinion on Therapeutic Patents2005237
7Anticancer carbonic anhydrase inhibitors: a patent review (2008 – 2013)Expert Opinion on Therapeutic Patents2013226
8Schiff bases in medicinal chemistry: a patent review (2010-2015)Expert Opinion on Therapeutic Patents2017208
9Anti-infective carbonic anhydrase inhibitors: a patent and literature reviewExpert Opinion on Therapeutic Patents2013203
10Sulfonamides: a patent review (2008 – 2012)Expert Opinion on Therapeutic Patents2012201
11Solid lipid nanoparticles: a review on recent perspectives and patentsExpert Opinion on Therapeutic Patents2020179
12Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent reviewExpert Opinion on Therapeutic Patents2013172
13Therapeutic effects of EGCG: a patent reviewExpert Opinion on Therapeutic Patents2016167
14Quinazoline and quinazolinone as important medicinal scaffolds: a comparative patent review (2011–2016)Expert Opinion on Therapeutic Patents2018165
15Taxane anticancer agents: a patent perspectiveExpert Opinion on Therapeutic Patents2016162
16Recent advances in therapeutic chalconesExpert Opinion on Therapeutic Patents2004160
17Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008–2018)Expert Opinion on Therapeutic Patents2018160
18Modulation of carbonic anhydrase activity and its applications in therapyExpert Opinion on Therapeutic Patents2004159
19Carbonic anhydrase inhibitors and activators and their use in therapyExpert Opinion on Therapeutic Patents2006158
20Recent developments in CCR2 antagonistsExpert Opinion on Therapeutic Patents2009158
215-Lipoxygenase inhibitors: a review of recent developments and patentsExpert Opinion on Therapeutic Patents2010157
22Urease inhibitors as potential drugs for gastric and urinary tract infections: a patent reviewExpert Opinion on Therapeutic Patents2011153
23Coumarin-based drugs: a patent review (2008 – present)Expert Opinion on Therapeutic Patents2012153
24Sirtuin activatorsExpert Opinion on Therapeutic Patents2009150
25The development of novel therapies for rheumatoid arthritisExpert Opinion on Therapeutic Patents2008147
26Deuterated drugs: where are we now?Expert Opinion on Therapeutic Patents2014145
27GPR119 agonists for the treatment of type 2 diabetesExpert Opinion on Therapeutic Patents2009142
28Piperazine derivatives for therapeutic use: a patent review (2010-present)Expert Opinion on Therapeutic Patents2016140
29Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesityExpert Opinion on Therapeutic Patents2003139
30Carbonic anhydrase inhibitors and their potential in a range of therapeutic areasExpert Opinion on Therapeutic Patents2018138
31Berberine and its derivatives: a patent review (2009 – 2012)Expert Opinion on Therapeutic Patents2013134
32Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015)Expert Opinion on Therapeutic Patents2016134
33Pharmacological effects of berberine and its derivatives: a patent updateExpert Opinion on Therapeutic Patents2016131
34Betulinic acid and its derivatives: a patent review (2008 – 2013)Expert Opinion on Therapeutic Patents2014128
35Acetylcholinesterase inhibitors: a patent review (2008 – present)Expert Opinion on Therapeutic Patents2012127
36Novel sulphonamide derivatives for the treatment of cancerExpert Opinion on Therapeutic Patents2000125
37Carbonic anhydrase inhibitors: an editorialExpert Opinion on Therapeutic Patents2013125
38Potential pharmacological uses of chalcones: a patent review (from June 2011 – 2014)Expert Opinion on Therapeutic Patents2015125
39Topical drug delivery systems: a patent reviewExpert Opinion on Therapeutic Patents2016123
40Discovery and development of antimitotic agents that inhibit tubulin polymerisation for the treatment of cancerExpert Opinion on Therapeutic Patents2002122
41Tanshinone II-A: new perspectives for old remediesExpert Opinion on Therapeutic Patents2013122
42Biodegradable thermosensitive copolymer hydrogels for drug deliveryExpert Opinion on Therapeutic Patents2007121
43Novel therapies for glaucoma: a patent review 2007 – 2011Expert Opinion on Therapeutic Patents2012121
44Benzofuran derivatives: a patent reviewExpert Opinion on Therapeutic Patents2013120
45Biological activities of guanidine compoundsExpert Opinion on Therapeutic Patents2009119
46Multicomponent reactions (MCR) in medicinal chemistry: a patent review (2010-2020)Expert Opinion on Therapeutic Patents2021115
47The emerging role of P-glycoprotein inhibitors in drug delivery: a patent reviewExpert Opinion on Therapeutic Patents2011111
48Phospholipase A2inhibitors as potential therapeutic agents for the treatment of inflammatory diseasesExpert Opinion on Therapeutic Patents2010110
49Recent advances in the therapeutic applications of pyrazolinesExpert Opinion on Therapeutic Patents2012109
50Terpenes and derivatives as a new perspective for pain treatment: a patent reviewExpert Opinion on Therapeutic Patents2014109